Stock Price, News, Quote and Profile of IMMUNOPRECISE ANTIBODIES LTD(NASDAQ:IPA) stock

IMMUNOPRECISE ANTIBODIES LTD

NASDAQ:IPA (9/28/2023, 7:00:03 PM)

1.88

+0.02 (+1.08%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryLife Sciences Tools & Services

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)09-14 2023-09-14/bmo

Earnings (Next)12-13 2023-12-13/bmo

Ins OwnersN/A

Inst Owners5.74%

Market Cap46.88M

Shares24.94M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts80

IPO01-30 1987-01-30

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The company is headquartered in Victoria, British Columbia and currently employs 102 full-time employees. The firm offers species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program- platforms. The company leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its technologies in bio platform-based antibody discovery. The company offers a selection of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma licensing for research purposes. Its services include specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners. The firm offers support to its partners, including rapid multi-omic analysis, customized project design, target identification and preparation, an on-site vivarium, and others.